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Abstract The clinical success of allogeneic hematopoietic
stem cell transplantation (HSCT) depends on the appropriate
reconstitution of the host’s immune system. While recovery
of T-cell immunity may occur in transplant recipients via
both thymus-dependent and thymus-independent pathways,
the regeneration of a population of phenotypically naive T
cells with a broad receptor repertoire relies entirely on the de
novo generation of T-cells in the thymus. Preclinical models
and clinical studies of allogeneic HSCT have identified the
thymus as a target of graft-versus-host disease (GVHD), thus
limiting T-cell regeneration. The present review focuses on
recent insight into how GVHD affects thymic structure and
function and how this knowledge may aid in the design of
new strategies to improve T-cell reconstitution following
allogeneic HSCT.
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Introduction
Present cytoreductive conditioning regimens in the context
of hematopoietic stem cell transplantation (HSCT) cause
defects within the immune system. Either transient or
protracted in nature, the post-transplant immune deficiency
can last for more than a year and is invariably associated
with an increased risk for opportunistic infections, inflam-
mation, reactivation of latent infections, disease relapse,
and the development of secondary malignancies. Hence,
rebuilding innate and adaptive immunity is a critical issue
for patients receiving HSCT, as is discussed elsewhere in
this issue of Springer seminars in Immunopathology.
The process of post-transplant immune reconstitution
depends on two mutually non-exclusive pathways, includ-
ing (1) the clonal expansion of donor graft- and residual
host-derived mature hematopoietic cells in peripheral
tissues of the host and (2) the de novo generation of cells
of the lymphoid and myeloid lineages from the transferred
hematopoietic stem cells (HSC). Whereas the natural
immune system (i.e. epithelial barriers, granulocytic cells,
phagocytes, and natural killer cells) typically recovers
within a few weeks post-transplant, the renewal of the
adaptive immune system is subject to a complex and slow
process which usually takes months (for B cells) to years
(for T cells) to be accomplished, even under favorable
conditions (see article by J. Storek in this issue)
Multiple parameters determine the speed of T-cell
reconstitution following HSCT: host factors such as age,
gender, type of conditioning and underlying pathology;
genetic differences between donor and host; stem cell
source; post-HSCT events such as acute and chronic graft-
vs.-host disease (GVHD) and their respective therapies;
relapse of malignancy; and infection by various microbial
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pathogens contribute to the kinetics of peripheral T-cell
recovery [1–15]. Early T-cell immunity present in trans-
plant recipients may be provided by residual, conditioning
resistant host T cells or by an inadvertent or intentional
therapeutic transfer of mature T cells of donor origin
[7, 16–19]. As the oligoclonal expansion of these cell
populations confers, however, only a limited degree of
immune competence, new T cells need to be generated
which, in turn, necessitates a functionally intact thymus.
The thymic generation of new Tcells assures the long-term
regeneration of a broad T-cell antigen receptor (TCR)
repertoire able to recognize a wide range of antigens. The
cellular and molecular mechanisms operational in the main-
tenance of thymic function in healthy, diseased, or aged
individuals have therefore received considerable attention
over the last few years. The collected insights reveal that
thymus-dependent T-cell reconstitution may be limited by
age-related thymic changes and by transplant-related toxicities
stemming from conditioning or graft-vs.-host disease.This
review discusses recent insight into how acute and chronic
GVHD affect thymic function and how a detailed understand-
ing of the molecular and cellular mechanisms of these
immunopathologies may lead to novel therapeutic approaches
that boost thymic function after HSCT.
Normal postnatal thymic T-cell maturation and export
The thymus is the primary site of T lymphopoiesis during
fetal and early postnatal life (for extended reviews see
references [20–24]). Organized into the subcapsular region,
the cortex, the cortical-medullary junction, and the medulla,
the cellular architecture of the thymus is highly conserved
between different vertebrate species and may hence reflect
a functional importance for this partition. As the thymus
does not contain hematopoietic precursor cells with a
capacity for unlimited self-renewal, T-cell progenitors are
continuously recruited to this site from the bone marrow via
the blood (see article by D.A.Zlotoff in this issue). These
precursors enter the thymus at the cortico-medullary
junction and, once positioned within the thymic microen-
vironment, develop there in an ordered maturational
sequence to phenotypically and functionally mature T cells
[25]. Thymopoiesis relies upon different signals which are
provided by a functionally competent stromal network.
This scaffold contains thymic epithelial cells (TEC),
bone-marrow-derived cells and mesenchymal cells [26,
27] (see below). Positive and negative selection effected by
cortical (c) and medullary (m) TECs and dendritic cells
(DCs) shape a repertoire of TCRs that respond to a
seemingly unlimited array of foreign (‘Non-Self’) antigens
while remaining unresponsive to the host’s own tissues
(‘Self’).
The thymic stromal compartment
All non-lymphoid cells of the thymus are commonly
referred to as stroma although their functional importance
would identify them more appropriately as thymus paren-
chyma. TECs constitute the major component of this three-
dimensional scaffold. Contrary to all epithelia in other
tissues, the vast majority of TECs lack the typical cell
polarity of epithelia and are not placed on a basal
membrane but are arranged in a three-dimensional orienta-
tion so that their dendrite-like processes form cell–cell
contacts which create a continuous network [23, 26, 27]. In
addition to TECs, the thymic stromal compartment also
contains mesenchymal cells such as reticular fibroblasts and
hematopoietic cells including DCs and macrophages.
Together, these cells form a complex microenvironment
that is not only competent to attract blood-borne precursors
but that is also uniquely capable to induce commitment to a
T-cell lineage and to efficiently support the survival,
expansion, differentiation, and selection of thymocytes so
that functionally and phenotypically mature T cells are
generated [20, 28].
TECs derive exclusively from the endodermal lining of
the third pouch in mice and of the third and fourth pouch in
humans [27, 29]. Recent experimental evidence has
unequivocally established in the fetal mouse that a single
intrathymic epithelial cell can develop into the different
TEC subpopulations required for the establishment of a
functional thymic microenvironment [30, 31]. Whether such
a thymic epithelial stem cell exists in the postnatal thymus also
under physiological conditions has not yet been unequivocally
proven. Once a thymus primordium is formed, the TEC
precursors differentiate into discrete cortical and medullary
epithelial subsets, a step that is initially independent of signals
from immigrating hematopoietic cells [32]. Embryonal and
postnatal TEC proliferation and differentiation depend on
signals mediated by epithelial cell mitogens, such as Fgf7
(fibroblast growth factor-7; a.k.a. keratinocyte growth factor)
[33–36] (see below). The continued development and
subsequent maintenance of the separate cortical and medul-
lary compartments require reciprocal interactions between
developing thymocytes and TECs, a process coined thymic
crosstalk [37]. Although thymic stroma cells expand rapidly
during mouse fetal development and continue to do so until
week 4 after birth, the proportion of these cells compared to
total thymic cellularity decreases progressively to a ratio of
one stromal cell to on average of 440 thymocytes at 4 weeks
of age and to approximately 320 thymocytes after puberty.
These extensive changes are paralleled by a continuous
turnover of thymic stromal cells resulting in a complete
replacement of the TEC compartment every 10 to 14 days
[38, 39]. Even though the number of human TECs still
expands in the first year after birth, both size and function of
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the thymus gradually diminish with and following the
second year of life [40–42].
The population of thymic epithelia is phenotypically and
functionally heterogeneous not only between the structurally
distinct cortical and medullary compartments but also
within these domains. While a detailed analysis of TEC
numbers and phenotype has not yet been performed for
the human thymus, quantitative data and a description of
lineage- and development-specific cell markers is available
for mice [38, 43]. For example, the expression of the
cytokeratins-5 (K5) and K18 in conjunction with the
detection of a UEA-1 binding lectin and at times other
not yet well characterized cell surface glycoproteins allow
to identify cTECs and mTECs as well as subpopulations
within these particular groups of thymic epithelia (murine
major cortical TECs display a K18+ K5−UEA-1−MTS10−
phenotype, the minor cortical TECs are K18+K5+UEA-
1−MTS10−, major medullary TECs are characterized as
K5+MTS10+ and minor medullary epithelial cells stain
K18+ UEA-1+ [20, 35, 44]). The microenvironment built by
cTECs supports the initial (i.e. most immature) develop-
mental stages in intrathymic T-cell development and
enforces the probing of the TCR affinity required for
positive selection. In contrast, mTECs together with DCs
enriched at the cortical-medullary junction but also dis-
persed throughout the medulla are responsible for negative
thymic selection.
By virtue of specialized TEC subpopulations, the thymus
is able to generate tolerance not only to ubiquitous self-
antigens but also to antigens that are typically expressed in
a tissue-restricted fashion. Whereas the need for negative
selection of TCR specificities recognizing the most com-
mon if not all self-antigens was appreciated as a necessity
to effect meaningful central T-cell tolerance, the molecular
control of this vital process remained for a long time largely
enigmatic. It is now well established that mTECs hold the
unique capacity to ectopically express and present a vast
array of different organ-specific antigens which provides a
‘molecular mirror of peripheral Self’ [45, 46]. Hence, this
promiscuous expression permits the negative selection of
TCRs that recognize with high affinity tissue-restricted
antigens (TRA) when complexed to self-major histocom-
patibility complex (MHC) molecules [45, 47]. Some of
these TRAs are in their expression under the control of the
transcription factor autoimmune regulator (Aire) [48]. Lack
of Aire expression is the genetic cause of the autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy
(APS-1) syndrome, an autosomal recessive disorder marked
by the persistence of autoreactive T cells in the periphery
[49]. Direct evidence for a decisive role of Aire in negative
thymic selection has been provided by experiments with
TCR transgenic mice where expression of the cognate
antigen is under the control of Aire [50, 51]. Under these
experimental conditions, a correlation was established
between the level of Aire expression, the number of TRA-
specific transcripts controlled by Aire and the extent of
negative selection affecting T cells with a TCR specific for
a given TRA [51]. The precise regulation of Aire
expression is thus indispensable to shape correctly a TCR
repertoire that is devoid of high affinity specificities
directed at self-antigens. Since the process of clonal
deletion of self-reactive T cells is not entirely efficient,
additional mechanisms are fortunately in place that secure
the induction of self-tolerance. For example, the thymus
generates a population of regulatory T cells (Treg) that is at
present characterized by their signature CD4+CD25+
phenotype and the expression of the transcription factor
Foxp3. The function of Treg is to control those self-reactive
T cells that have wrongly escaped negative thymic selection
and settled in peripheral tissues [52–54]. For their forma-
tion, Treg require a TCR that binds with a high enough
affinity to its cognate ligand on TECs and thymic DCs. It
remains, however, unknown how this level of TCR affinity
shuns the typical fate following a high affinity interaction
with a MHC/peptide complex, an event leading in
conventional T cells to negative selection. The relative
contribution of TEC and DC in fostering this generation of
Treg is still not settled and awaits to be resolved [55, 56].
Thymic export and its detection
T cells are continuously exported to peripheral lymphoid
tissues by mechanisms that are only incompletely understood
at present but that are independent of a feedback mechanism
sensing the number of peripheral T cells [56]. Informative cell
surface markers that accurately identify recent thymic
emigrants (RTE) among mature peripheral T cells are lacking
for both mice and humans. Consequently, it has been
difficult in practice to precisely determine in vivo the thymic
export of new T cells during steady-state and under
conditions of disease. The expression of CD45 splice
variants is commonly, but not always correctly [57], used
as a marker to enumerate naïve (i.e. CD45RA+) T cells.
Detection of other cell surface markers such as CD62L,
CD27, CD31, or CD103 (αEβ7 integrin) may also aid in the
identification of human naive T cells but again, their cell
surface expression is not exclusive for RTE [2, 9, 58–60].
Thymic T-cell output in humans and in mice has been
quantified in more recent studies by measuring T-cell
receptor rearrangement excision circles (TRECs) [2, 3, 41,
61–74]. These extrachromosomal, non-replicating DNA
circles are a byproduct of the rearrangement of the TCR α/
δ locus (TCRAD) and are exclusively generated during the
CD4+CD8+ stage of intrathymic T-cell development. Two
sequential rearrangement steps during human TCRαβ+
thymocyte development result in the formation of signal
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joints (sj) TRECs and coding joints (cj) TRECs. Since these
steps are identical in ~70% of all cells, a PCR-based analysis
of TRECs is feasible and practical [75, 76]. TRECs are
measured from DNA extracted from a defined population of
typically 105–106 blood mononuclear cells or sorted CD4+ or
CD8+ T cells. The calculated number of TRECs per cell is
then referred to as TREC content. In addition to the
measurement of sjTRECs derived from the TCRAD locus,
measurements of TRECs from the V(D)J rearrangements of
the β-chain locus have now also been successfully employed
to determine RTE [77].
New T cells are generated in the thymus throughout life
but the size of this organ and in consequence the number of
RTE changes as a function of age [11]. Thymic T-cell
output is in humans particularly high during the fetal and
perinatal period, but thymopoietic function and consequently
the exit of naïve T cells decrease swiftly following the first
year of life and are again further diminished shortly before
the onset of puberty. Although structural and functional
involution are characteristic hallmarks of the aging thymus
and are already present at a relatively young age, phenotyp-
ically naïve TREC+ cells can still be detected in the
peripheral blood of octogenarians and even older individ-
uals [19, 78, 79]. Physiological thymic involution affects
both the lymphoid and the stromal compartments of the
thymus, and is paralleled by an increase in perivascular
space and adipose tissue [38, 80].
Pathways of post-transplant T-cell regeneration
Preclinical and clinical studies have interrogated the
respective roles of peripheral expansion and thymus-
dependent T-cell maturation in the process of T-cell
regeneration following conditioning-dependent lymphode-
pletion and HSCT. Results from these studies [1, 2, 5–9, 11,
15, 19, 60, 67, 81, 82], indicate that T-cell reconstitution
occurs via both thymus-independent and thymus-dependent
pathways but that their individual kinetics are variable
owing to (1) genetic differences between donor and
recipient, (2) the age of the recipient, (3) the use of T-cell
depleted (TCD) vs. unmanipulated grafts, (4) the infusion
of bone marrow vs. mobilized peripheral blood stem cells,
(5) myeloablative vs. non-myeloablative pre-treatment, and
(6) the absence vs. presence of transplant-related compli-
cations such as GVHD.
Thymic-dependent T-cell regeneration in humans
During life, peripheral T cellularity is primarily regulat-
ed by homeostatic expansion [19, 83]. Under physiolog-
ical steady-state conditions, thymic T-cell export clearly
plays only a minor role in maintaining regular T-cell
numbers in peripheral lymphoid tissues, even in the face
of the several million naïve T cells that are daily exported
from a normal thymus at young age [84]. Under
conditions of severe lymphodepletion, the generation of
new TCR specificities is, however, critical to regenerate a
peripheral T-cell compartment that is able to provide
sustained adaptive immunity. Indeed, the degree of post-
transplant TCR repertoire contraction is correlated to host
immune incompetence and hence determines clinical
outcome [85]. Although there is some evidence for
extrathymic differentiation at various anatomical sites
[86], the most efficient maturation of new T cells occurs
in the thymus. Hence it is the extent of thymic function as
influenced by senescence, cytoreductive treatment or
transplant-related toxicities (TRT) that will determine the
efficiency by which the peripheral T-cell compartment is
reconstituted following lymphodepletion [16, 19, 62, 68,
87–90].
Several weeks are required before mature thymic T cells
arise from bone marrow-resident precursors [84, 91]. It is
therefore not surprising that a substantial restoration of the
T-cell compartment with naïve cells constitutes a very time-
consuming process that requires even under favorable
conditions at least 1–2 years [82]. Independent of specific
transplantation protocols employed, the recovery of the
peripheral T-cell compartment is typically marked by the
emergence of CD45RA+, CD62L+ T cells that harbor
TRECs (i.e. bona fide RTEs [2, 3, 6, 9, 13, 15, 16, 18,
19, 62, 67, 68, 70, 81, 82, 89, 92–101]). The quality of the
renewing T-cell compartment is at present most precisely
measured by functional T-cell assays such as the measure-
ment of pathogen-specific T-cell proliferation and by the
assessment of TCR diversity using either flow cytometric
quantification of TCRVβ usage or PCR-based spectratyping
of the complementarity determining region 3 (CDR3) of the
TCR-β chain [9, 62, 82, 85, 96–98, 102–107].
Thymic selection: the allogeneic HSCT concern
TCR selection depends on the exposure of developing
lymphoid precursors to self-peptide/MHC complexes on
different thymic stromal cell types. Positive thymic selection
occurs in the cortex where TCRs are selected that display an
intermediate affinity for the combination of self-peptides and
self-MHC complexes expressed by cTECs. Surviving TCR
specificities are then monitored in the medulla for reactivity
to self-peptides presented by either mTECs or by bone
marrow-derived DCs in a process termed negative selection.
Under non-transplant conditions, the MHC haplotype
expressed by hematopoietic and epithelial stromal cells is
identical and this constellation assures that the MHC
molecules on which positive and negative selection occurs
are the same as those used for foreign antigen presentation by
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blood-borne, professional antigen presenting cells (APC)
resident in all peripheral tissues. This physiological situation
is contrasted by conditions that arise in HSCT recipients.
Because of their radiation-resistance and non-hematopoietic
origin, TECs remain of host origin. In contrast, the thymic
stromal cells of hematopoietic origin (DCs, macrophages
and other cells) are ablated by radio/chemotherapy and hence
relatively quickly replaced by donor-type cells following
HSCT. In autologous HSCT or under conditions of complete
MHC match between donor and host, the HLA molecules
presented on thymic stromal cells remain identical for
positive and negative thymic selection. In HLA-mismatched
HSCT, radioresistant TECs will express the recipients’
haplotype but the bone marrow-derived cells will be of
donor origin and hence of a different haplotype. This
variance in MHC restriction is thought to influence thymic
T-cell repertoire selection and, in consequence, that of the
peripheral T-cell pool. Indeed, clinical data suggest that TCR
repertoire diversity is only mildly perturbed in recipients of
unmanipulated bone marrow from HLA-identical, related
donors whereas a skewed TCR repertoire (at least for the first
years after transplantation) is noted in recipients of unrelated
or HLA-mismatched, related donors, particularly under
conditions where the bone marrow inoculum was depleted
of T cells [97, 108, 109].
Several specific aspects related to the difficulty of
predicting TCR repertoire selection and T-cell function in
HLA-disparate transplant recipients (be it in the absence or
presence of GVHD) require a closer investigation. To
address these issues in the most extreme situation, we will
focus here on the haploidentical HSCT setting. Although
naïve T cells emerge after intense conditioning and
haploidentical HSCT [110–112], little is known with
reference to the TCR repertoire complexity generated, the
MHC restriction and the functional competence of the
emerging T cells. Given the disparity in HLA expression
between the epithelial cells required for positive selection
and the hematopoietic cells involved in negative thymic
selection, a distortion of the regenerating TCR repertoire is
to be expected. Indeed, autoreactive T cells can be
recovered at a relatively high frequency in mice that
express a particular MHC class II molecule only on cTECs,
but not on DCs or mTECs [113, 114]. Related to this
situation are observations that an unopposed positive
selection due to the absence of MHC class II expression on
mouse thymic DCs generates a T-cell repertoire which
causes either autoimmune colitis [115], or autologous GVHD
in normal syngeneic mice [116], or chronic GVHD in MHC-
disparate recipient mice [117]. These experimental findings
underscore the necessity for correct negative thymic selec-
tion and suggest that an only positively selected TCR
repertoire includes autoreactive TCR specificities with the
evident potential to cause autoimmune pathology. Hence, a
difference in the set of MHC-restricting elements between
positively selecting cTECs and negatively selecting DCs
may allow the survival and thymic export of autoreactive T
cells. In this context it is however interesting to note that an
effective reconstitution of TCR diversity and function
appears to be possible in disease-free patients following the
engraftment of TCD haploidentical bone marrow cells [118–
126]. These individuals produce within 2 to 3 years a
repertoire of TREC-positive T cells that displays a normal
Vβ complexity. While further studies with larger patient
cohorts will be needed to confirm independently these
results, the data so far suggests that thymic positive and
negative selection can remain undisturbed after engraftment
of HLA-mismatched HSC. Specifically, these results imply
that the emerging T-cell compartment exhibits a TCR
repertoire comparable to that of recipients of TCD and
HLA-matched grafts [127]. As encouraging as these results
appear, they are difficult to interpret and the impact of
correct negative thymic selection for the generation of these
cells will need to be investigated in more detail. Nonetheless,
the principle still stands that MHC-restricted T-cell selection
is most efficient and robust under conditions where stromal
cells and bone marrow-derived cells share an identical MHC
[128, 129].
Evidence exists both from experimental animal models
and from transplanted immunodeficient patients that cells
other than TECs can execute positive thymic selection.
For example, the intrathymic injection of fibroblasts or
medullary epithelial-like cells select T cells that are
restricted to the MHC present on the transferred cells
[130–132]. Reconstitution of athymic mice with allogeneic
thymic stromal cells results in the formation of mature,
functionally competent T effector cells that are restricted to
thymic donor but not recipient MHC molecules [129].
Alternatively, developing thymocytes can be positively
selected by hematopoietic cells and the transgenic expres-
sion of MHC class II molecules on immature thymocytes
of the mouse is sufficient to select functionally competent
CD4+ T cells with a mature phenotype and a polyclonal
TCR repertoire [133]. While some of this experimental
evidence argues that a thymus stromal defect can be
efficiently corrected by allo- (and possibly xenogeneic)
thymic grafts, it is the second set of data that would
claim that thymocyte-thymocyte interactions suffice for
positive selection of CD4+ T cells (at least in the mouse,
where MHC class II molecules are not normally expressed
by thymocytes and T cells). Taken together, these
experimental models may have uncovered a previously
unappreciated, independent pathway of positive thymo-
cyte selection that may play a physiological role in species
such as man where thymocytes physiologically express
MHC class II molecules. Strikingly, the selection, MHC-
dependent amplification and survival of mature T cells
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educated either on TEC or non-TEC MHC appear to be
equivalent, at least under the experimental conditions
tested [134].
Support for a concept that the thymus holds the capacity
to generate a TCR repertoire which is not restricted to the
MHC haplotype expressed by TECs also comes from
patients with a complete DiGeorge anomaly that have been
transplanted with a postnatal, HLA-non-matched thymus
graft to achieve reconstitution of their T-cell compartment
[135, 136]. In these patients, mature host-type T cells are
detected as early as 6 months after transplantation. These
cells respond to nominal, T-cell-dependent antigens which
indicates that they are (if not exclusively, so at least
sufficiently) restricted to host-type MHC molecules [137,
137]. Although not yet formally demonstrated in trans-
planted patients with the complete DiGeorge anomaly,
indirect evidence would suggest that positive thymic
selection is mediated in these patients by bone marrow-
derived cells. However, it needs to be stressed that neither
vigor nor efficiency of this “non-canonical” selection
process has been established. It is therefore important to
address in more detail the MHC restriction bestowed on T
cells of athymic individuals grafted with non-HLA matched
thymic stroma and to test the functionality of their
peripheral T cells at both a molecular and expanded
functional level.
While it is tempting to speculate on the main function of
the thymic epithelial cells to establish a microenvironment
that promotes TCR expression in an MHC-unspecific
fashion whereas the organ’s hematopoietic components
control the TCR repertoire through an MHC-dependent
mechanism, several important issues related to selection
and hence central tolerance induction remain unanswered.
For example, the role of tissue restricted self-antigens
expressed by mTECs is not considered in this alternative
model. However, such antigens and the mechanism by
which they are expressed may be critical to prevent
autoimmunity. In view of this competence for promiscuous
gene expression, the epithelial thymic microenvironment is,
indeed, mostly unique and cannot be replaced by hemato-
poietic cells [45, 48].
GVHD as a major limitation of thymus-dependent
T-cell regeneration
Qualitative and quantitative restrictions related to the
thymus-dependent T-cell development have been causally
linked to a functionally incapacitated peripheral T-cell
compartment. Among the obstacles that influence thymus-
dependent T-cell regeneration, the age of the transplant
recipient and the treatment-related toxicities confound
thymic function the most.
Human thymus function in the context of acute GVHD
GVHD is a complication of allogeneic HSCTwhich can occur
in an acute and a chronic course, with each form highlighted
by different clinical features, and distinct kinetics in their
presentation due to differences in their respective pathome-
chanisms [10, 138–143]. Occurring at considerably high
frequencies in sibling donor recipients and unrelated donor
(URD) recipients, incidence and severity of acute GVHD
depend on several factors, including histoincompatibility, age,
graft composition, host environment, GVHD prophylaxis
method, and the type of host conditioning. Acute GVHD
manifests in a limited set of tissues, including the liver, skin,
gastrointestinal tract, and lung. Although clinical practice has
so far focused mainly on the involvement of these “typical”
organ targets, it is now broadly accepted that the host’s
lymphohematopoietic system serves as primary target of acute
GVHD [144].
The presence of acute GVHD in allogeneic HSCT
recipients is a major predictor for an increased probability to
be diagnosed with an opportunistic infection [3, 10, 69, 97,
127, 142, 145–147]. As the pool of potential HSC donors
increasingly includes genetically disparate, unrelated indi-
viduals [148], both frequency and severity of GVHD are
currently rising among transplant recipients. Consequently,
clinically relevant immunodeficiency will likely increase in
these patients. A detailed understanding of the GVHD-
related pathomechanisms that compromise the host’s im-
mune competence will thus be decisive to improve clinical
outcome.
GVHD severity is inversely correlated to the capacity
to recover T-cell immune competence [3, 69, 106, 149].
Both the immunosuppressive measures taken for GVHD
prophylaxis/treatment [6] and the immune-mediated
effects of acute GVHD per se are detrimental and account
for the observed T-cell deficiency [70]. As early as
30 years ago, clinical observations had identified the
thymus as a target of GVHD since morphological changes
affecting both the lymphoid and epithelial components of
the thymus could be observed in patients following
allogeneic HSCT [150–154]. Typical histological features
of GVHD-induced thymic dysplasia include the depletion
of cortical and medullary thymocytes, changes in the
number and composition of the different thymic epithelial
cell subpopulations, disappearance of the corticomedullary
demarcation, phagocytosis of cellular debris, and the
elimination of Hassall’s bodies [150, 155, 156]. The loss
of the regular tissue architecture is paralleled by deficits in
thymopoiesis as confirmed by a distorted TCR repertoire
and lower TREC levels when compared to healthy
controls [3, 68, 69, 157]. Although the lower TREC levels
in recipients of HSCT have been interpreted as the
consequence of a decreased thymic output due to GVHD,
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an alternative explanation also needs to be considered.
Indeed, some studies have failed to demonstrate an
association between TREC levels and the presence of acute
or chronic GVHD [66, 67] because TREC content is not
only affected by thymic output but also by the prolifera-
tive kinetic of both TREC+ and TREC- cells [70, 73, 74].
Thus, assessments of peripheral events such as cellular
expansion [158] and cell removal by death will need to be
combined with TREC analysis in order to draw informa-
tive conclusions with regard to changes in thymic export.
Pathomechanisms of thymic insufficiency: insights
from preclinical GVHD models
Preclinical allogeneic HSCT models have provided infor-
mative insight for a better understanding of GVHD. The
immunopathophysiology of acute GVHD may be divided
into three distinct but interrelated phases: (1) tissue damage
attributable to previous therapy and conditioning regimens,
(2) donor T-cell activation following interaction with
professional host-derived APC in a process termed ‘GVH
reaction’, and (3) injury of a limited number of target
tissues by multiple soluble and cellular effectors [10, 138,
141–143, 159–166]. The secretion of disease-promoting
cytokines, especially interferon (IFN)-γ, occurs in all three
phases [159, 160, 167–174] and as a single factor plays
hence a critical role in acute GVHD.
Experimentally induced thymic dysplasia mimics the
features typically observed in human GVHD, including the
loss of cortical cellularity, the lack of a cortex/medulla
demarcation, the absence of a regular composition and
organization of the different TEC subpopulations, the loss
of regular TCR repertoire selection, and the diminished
number of TREC+ cells [3, 4, 18, 44, 69, 151–154, 158,
173–184]. Whereas the effects of chemo- and radiotherapy
on thymic cell composition and architecture are well known
[185–187], the immunological mechanisms underlying
thymic injury have only recently begun to be investigated.
To this end, the transfer of parental Tcells into haploidentical
F1-progeny provides a specially adapted preclinical trans-
plantation model as it circumvents the need for irradiation
[188] and hence provides an experimental system to
investigate the direct impact of an anti-host immune
response on thymic structure and function. Under these
experimental conditions, thymic hypocellularity is primarily
the consequence of a depletion of the most populous
double-positive (DP. i.e. CD4+CD8+) thymocyte subset.
Two independent mechanisms account for this finding. The
first pathway encompasses the failure of resident CD3,CD4,
CD8 triple-negative (TN) thymocytes to proliferate ade-
quately. TN cells are further subdivided into four distinct
subsets based on their surface expression of CD44 and
CD25. Maturation within the TN compartment occurs in
the sequence CD25−CD44+ (stage I) → CD25+CD44+
(stage II)→ CD25+CD44− (stage III)→ CD25−CD44-
(stage IV) [189]. The progression of TN thymocytes to
the DP cell stage is paralleled under physiological steady-
state conditions by a 20- to 50-fold expansion in cell
number [190]. The frequency of stage I TN cells is
increased during acute GVHD in lieu of cells with a stage
III TN phenotype [173]. This observation is in keeping with
cell cycle analysis during acute GVHD demonstrating that
viable TN cells of stages II, III and IV are severely inhibited
in their in vivo proliferative capacity. This finding is of
relevance for T-cell development because only TN thymo-
cytes that have productively rearranged one of their TCRβ
gene loci are allowed to progress to the DP stage. A lack of
a strong clonal expansion therefore results in a failure to
generate a sufficiently large number of DP thymocytes
which leads to overt thymic atrophy [173]. The second
pathway leading to DP depletion concerns the increased
programmed cell death among DP thymocytes, an event
further contributing to thymic lymphopenia. Systemic
effects have first been taken into consideration to be the
reason for cell death. For example, experimental and
clinical observations indicate that high pharmacological
doses of glucocorticoids induce rapid apoptosis among
immature thymocytes [191]. A role of steroids in thymic
hypoplasia would in turn be consistent with the fact that the
hypothalamus-pituitary-adrenal axis is activated during
acute GVHD [192–194]. Pharmacologically blocking the
steroid receptor has, however, no influence on the frequen-
cy and absolute number of DP undergoing apoptosis during
acute GVHD, excluding the possibility that a systemic,
glucocorticoid-dependent mechanism accounts for the loss
of DP thymocytes [184].
Alloimmune-mediated effects on the thymic lymphoid
and stromal compartments must therefore be considered.
Recent analyses have focused on the architecture and
composition of the TEC subpopulations and revealed that
TECs undergo programmed cell death following transfer of
allogeneic T-cells into unconditioned, fully MHC-disparate
recipients [174]. Mainly cortical TECs are depleted in the
course of acute GVHD, identifying these particular stromal
cells as potential targets of allorecognition. Cortical TEC
reduction displays rapid kinetics since a substantial number
of K18+TECs has undergone programmed cell death as
early as 2 weeks after acute GVHD induction. Apoptotic
TEC are typically located in areas of elevated epithelial
density and adjacent to dying thymocytes. This feature is
not only apparent following fully MHC-mismatched HSCT
but also in an experimental setting in which the developing
thymocytes, but not TECs, are donor-matched and thus do
not constitute targets of an alloresponse [174]. Such data
clearly indicate that a disruption of the stromal compart-
ment as a consequence of an antigen-specific immune
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response is responsible for the disturbance of regular T-cell
development. This mechanism would be consistent with the
fact that donor-derived MHC-disparate T cells invade into
the recipients’ thymus, an event which has long been
recognized to represent a typical feature of acute GVHD
[152, 173, 174]. This invasion occurs even in the absence
of pretransplant conditioning. The infiltrating T cells are
detectable as early as 4 days after transplantation and their
number in situ moreover correlates directly with the extent
by which host thymopoiesis is disturbed. Definitive
evidence that TECs can serve as direct targets of an
alloimmune response has been gained from experimental
systems using reaggregate thymic epithelial grafts. When
grafts from fetal H-2bd mice are transplanted into athymic
H-2b recipients, they can be recognized and destroyed by
infused mature H-2b T cells. Importantly, this TEC injury
suffices to abrogate regular thymocyte (H-2b) maturation in
the ectopic thymi. In vitro experiments using co-cultures of
purified naive T cells and MHC-disparate TECs have further
established a direct and causative link between donor T-cell
activation by TEC alloantigens, leading to their secretion of
IFN-γ. This causes in TECs the activation of the IFN-γ-
responsive signal transducer and activator of transcription
(STAT)-1 molecule and caspase-mediated apoptosis of these
cells [174]. Hence, in addition to serving as disease-relevant
targets of a GVH reaction, TECs are also competent and
sufficient to prime naïve allogeneic T cells in the absence of
hematopoietic host-type APCs [147, 173, 174].
The view that TECs can cell-autonomously act as
professional APC for naive allogeneic T-cells is in keeping
with previous findings using a similar parent→F1 chimera
model [195, 196]. Here, subsets of high-affinity resting T-
cells were shown to become activated in vivo to class I and
II alloantigens presented selectively on non-bone marrow-
derived cells. The TEC’s unique capacity to prime naïve T-
cells and to be recognized as allogeneic targets during acute
GVHD may, however, be best accounted for by their
inherent competence to present antigens to naïve T cells
when compared to other epithelial cells that are regularly
targeted by T cells in the context of acute GVHD. For
instance, the transplantation of epithelia from thymic tissue
taken at an early stage of organogenesis when the anlage is
still devoid of DCs [197], causes acute rejection of the graft
following the direct recognition of TECs by the transferred
allogeneic T cells [198]. Indeed, TECs (but not other
epithelia) display a constitutive expression of MHC class I
and II molecules whose cell surface density may even
surpass that of DCs [199]. Moreover, TECs which are
organized in a three-dimensional fashion with only few
epithelial cell/cell contacts, provide thus a loose meshwork
easily accessible for alloresponsive immune cells. Although
the in vitro immunogenic potential of TECs is lower when
compared to hematopoietic professional APC [174], the
functional and phenotypic characteristics of the TECs may
render these cells nonetheless competent to activate T cells in
vivo. It remains to be firmly established whether naive
allogeneic T-cells actually enter the thymus, or whether this
capacity is restricted to T-cells already activated in the
periphery. Currently available experimental data addressing
similar questions in experimental settings unrelated to alloge-
neicity would support either conclusion [200–203]. The fact
that TECs may act as intrathymic APCs to activate naïve
donor T cells is also supported by evidence that acute GVHD
can be exclusively restricted to the thymus [174]. However,
thymus-restricted structural and functional changes are not
easily monitored by diagnostic tools currently available,
rendering the diagnosis of thymic GVHD rather difficult,
A detailed understanding of the primary target of thymic
GVHD is required to design novel strategies that may
prevent allorecognition by mature donor T cells. In fact,
because TECs act as competent APCs it is unlikely that a
vigorous depletion of host-derived hematopoietic APCs (as
part of pretransplant conditioning) will suffice to prevent the
activation of alloresponsive donor Tcells and hence preclude
the consequential injury to TECs. Indeed, the expression of
alloantigens (H-2d) exclusively on host non-hematopoietic
thymic stromal cells is sufficient to cause an accumulation
of transferred alloreactive donor T-cells (H-2b). These
thymus-infiltrating T-cells (CD8+> CD4+) display 2 weeks
after infusion an activated phenotype (i.e. are CD44high,
CD62Llow, CD69−) and secrete high concentrations of IFN-γ
either spontaneously or after restimulation in culture.
Moreover, extensive changes characterized by an altered
stromal architecture and aberrant host T-cell development
can be observed under conditions where alloantigens are
only present on non-hematopoietic stromal cells of the
thymus [174]. Taken together, these data clearly establish
that alloreactive donor T cells can also be primed in vivo
by TECs and that consequent changes in the composition,
organization and viability of thymic stromal cells severely
disturbs thymocyte maturation. With TECs efficiently
recognized by donor T cells, future therapeutic efforts
may therefore want to focus on strategies how to prevent
and/or repair epithelial damage (see below). If successful,
such endeavors are also likely to confirm a link between
subclinical GVHD that is exclusively restricted to the
thymus and an increased susceptibility for infections
observed in recipients of unrelated donor HSCT.
Thymic dysfunction as a link to autoimmunity
and chronic GVHD?
Although the number of allogeneic HSCT recipients who
have now survived for two to three decades is increasing,
only few of these individuals have fully regained their pre-
morbid state of immunological health. The pathogenesis for
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late complications of HSCT is multifactorial, with some of
these disorders displaying clearly an autoimmune pathology
[204]. Autoimmunity after HSCT has many hallmarks of
chronic GVHD, the latter being a pleiomorphic syndrome
with onset originally occurring between 3 and 24 months
after allogeneic HSCT [205]. While not all HSCT recipients
with autoimmune syndromes experience also symptoms of
chronic GVHD, there is a strong association between the
development of chronic GVHD and autoimmune disease in
HSCT recipients [206]. Experimental studies have thus far
proposed at least four distinct pathomechanisms to explain
chronic GVHD [207] implicating (1) regulatory cytokines
such as transforming growth factor-β (TGF-β) [208], (2)
autoreactive B cells [209], (3) the deficiency of Treg [210],
and (4) a failure in negative thymocyte selection to play a
critical role.
Reliable evidence for a responsibility of the thymus in
the pathogenic events leading to chronic GVHD has been
gained from different mouse transplantation models. In one
model, thymic injury in recipients (C57BL/6) is caused by
the infusion of MHC-mismatched donor CD8+ T cells
(C3H.SW). As a result, TCR repertoire selection among
recipient-type CD4+ T cells is severely altered by the
damaged thymic microenvironment and now includes
specificities that are reactive to self-antigens [211]. In
addition, these T cells are the result of an aberrant thymic
selection process as they induce all the hallmarks of chronic
GVHD when adoptively transferred into secondary naïve,
syngeneic (C57BL/6) recipients. In contrast, these same T
cells elicit an acute form of GVHD when injected into
allogeneic (C3H.SW) mice. Hence, thymic damage in the
course of acute GVHD will select a repertoire of T cells that
is in due course able to cause autoimmune manifestations
reminiscent of chronic GVHD. In keeping with these
observations are results from bone marrow chimeric mice
in which negative thymic selection of CD4+ T cells by
hematopoietic APC is impaired due to the absence of MHC
class II expression on DC but not TECs [116, 117]. As a
consequence, the selected repertoire of T cells contains
overtly autoreactive cells that induce chronic GVHD in
MHC-mismatched recipients (C57BL/6-MHC II−/−→C3H.
SW) and an ‘autoimmune GVHD’-like syndrome in
matched (C57BL/6-MHC II−/− → C57BL/6) chimeras.
Importantly, acute GVHD not only affects negative T-cell
selection in the thymus but also impairs development of
Treg [212] which can prevent chronic GVHD [209]. Taking
these preclinical data together, acute GVHD causes thymic
injury, harms the TCR repertoire selection and consequent-
ly changes GVHD from an acute to a chronic form.
Although not all cases of human acute GVHD evolve into
chronic GVHD, the former has nonetheless been recog-
nized as a risk for the latter. It is therefore intriguing to
speculate that the early post-transplant impairment of TEC
function and hence TCR selection provide an etiological
link between the alloreactivity of acute GVHD and aspects
of autoimmunity typically seen in the course of chronic
GVHD [147]. In this context, the loss of Aire+ TECs may
constitute a crucial mechanism by which central tolerance
induction is disturbed since this particular subpopulation of
TECs is both instrumental in negative selection of
autoreactive TCRs and in the generation of natural Treg.
Preliminary data from our laboratory certainly indicate a
dysregulation of Aire expression in experimental acute
GVHD. Further work is, however, still required to confirm
that such a mechanism is indeed operational in the
induction and/or the maintenance of chronic GVHD.
Interventions to improve immune regeneration
via protection of thymic epithelium: the role
of fibroblast growth factor-7
Strategies aimed at enhancing thymic function hold the
promise to ameliorate post-transplant T-cell immunodefi-
ciency. Both prophylactic and therapeutic approaches may
be effective to enhance the (residual) thymic function or,
alternatively, (re-) generate new thymic stromal elements.
Several strategies to improve immune reconstitution have
so far been developed in preclinical models but only few
have for now been successfully translated to clinical
practice (reviewed in references [4, 12, 213]). Here,
interventions shall be discussed that seek to prevent TEC
injury after allogeneic HSCT.
Fibroblast growth factor (Fgf)-7 (a.k.a. keratinocyte growth
factor) is a potent epithelial cell mitogen that belongs to the
large family of the structurally related Fgfs [214]. Fgf7 is
currently an approved drug for the prophylaxis of oral
mucositis in conditioned transplant recipients [215, 216]. Its
action as a trophic factor and its ability to protect against
radio- and chemotherapeutic damage [214] serves as
rationale to test the impact of Fgf7 on recovery of TECs
following conditioning and HSCT. This concept has received
further support by the assumption that the postnatal thymic
epithelial compartment may continue to require growth
regulating signals including possibly endogenous Fgf7 since
postmitotic TECs are continuously replaced by the progeny
of immature TEC precursors [38]. Indeed, thymic expression
of Fgf7 is sustained throughout life [34]. To exert its
biological activity, Fgf7 binds to and activates the IIIb
variant of the FgfR2 receptor (FgfR2IIIb) which in the
thymus is exclusively expressed on TECs [33, 35, 44, 217].
In response to systemic treatment of normal mice with
exogenous Fgf7, the postnatal thymic microenvironment
undergoes specific changes. These in vivo alterations are
characterized by a robust expansion of both mature and
immature TECs within days of Fgf7 exposure even as the
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architectural organization of all TEC populations remains
unaltered [35]. Due to an increased proliferation rate
following Fgf7 stimulation, the resultant enlargement of the
TEC scaffold accommodates a higher lymphoid cellularity
while keeping a normal thymocyte–TEC ratio. In addition it
is also likely that the exposure of TECs to a pharmacological
dose of Fgf7 changes the quality the TEC compartment. In
support of such an assumption are results from experimental
models where a single course of Fgf7 suffices to reverse the
age-related decrease in thymocyte numbers and to restore the
architecture and cellular composition of the thymic stromal
microenvironment [218]. Moreover, exposure of mice of any
age to exogenous Fgf7 also causes an increase in thymo-
poietic activity and reconstitution of the peripheral T-cell
compartment in syngeneic or allogeneic transplant recipients
preconditioned with chemo- or radiotherapy [34, 219].
Similarly, rhesus macaques engrafted with autologous HSC
and treated with Fgf7 display an enhanced T-cell recovery as
assessed by an increase in TREC+ cells [220]. When used in
preclinical models of acute GVHD, the systemic administra-
tion of Fgf7 preserves TEC architectural organization,
cellularity and function [44]. As a result, normal T-cell
development is maintained regardless of alloreactive donor T
cells in the thymus and ongoing GVHD in other typical
target organs. In consequence, the administration of Fgf7
prevents the emergence of a repertoire of autoreactive T cells
that promotes the development of experimental chronic
GVHD [211]. Exploiting these effects for clinical use,
studies are now under way in lymphopenic HSCT recipients
to assess whether Fgf7 can enhance T-cell recovery either in
the presence or absence of a chemical androgen blockade
which is given to further protect TECs [213, 221–223]. Anti-
androgen treatment has previously been proposed as an
independent measure to correct the transplant-related im-
mune deficiency because the senescence-driven thymic
involution has been linked to physiological changes in sex
steroid hormone production [42, 224, 225]. Indeed, andro-
gen receptors are expressed on TECs and their binding to
sex steroids inhibits thymopoiesis although the molecular
mechanisms by which this occurs are not yet precisely
known [226]. These data raise reasonable hope that Fgf7
alone or in combination with other agents (such as androgen
blockade) can be used to enhance T-cell reconstitution in
lymphopenic recipients of allogeneic HSCT.
The molecular mechanisms by which Fgf7 influences TEC
function are currently under investigation. Under physiologi-
cal conditions, Fgf7 is expressed within the thymus both by
stromal cells and by T cells at specific developmental stages
[33, 227]. Experiments using both mice deficient in
FgfR2IIIb expression or in vitro conditions where mesen-
chymal cells are physically removed from embryonic thymus
lobes have revealed the importance of Fgf signaling during
early thymus organogenesis [33, 228, 229]. The postnatal
thymic epithelial compartment may, however, continue to
require growth-regulating signals, including endogenous
Fgf7, whose thymic expression is sustained throughout life.
A recent study designed to examine the molecular and
cellular mechanisms by which Fgf7 stimulates thymic T
lymphopoiesis in normal adult TECs has concluded that
FgfR2IIIb is expressed by both mature cortical and medul-
lary as well as immature thymic epithelia [35]. Upon
exposure to exogenous Fgf7, these stromal cell subsets
proliferate and express several growth and differentiation
factors, including different members of the family of Wnt
molecules and bone-morphogenetic proteins [35]. In conse-
quence of changes in gene expression in TECs, a robust and
sustained increase in thymopoiesis occurs which is initiated
as a single wave affecting first the number of the most
immature T-cell precursors and subsequently that of more
mature thymocytes. This effect of enhanced thymopoiesis is
uniquely dependent on the exposure of the stromal microen-
vironment to Fgf7 as the transfer of the earliest intrathymic
T-cell precursor from Fgf7-treated donor mice to naive (i.e.
untreated) recipients fails to impart enhanced thymopoiesis
and export of mature T cells to the periphery.
An increase in thymopoiesis and thymic T-cell export
appears to be highly beneficial for lymphopenic individuals
not at least because the thymus does not sense peripheral T
lymphopenia and is hence unable to gauge its T-cell export
accordingly. Consequently, any increase/enhancement in thy-
mic output should positively affect the process of replenishing
the peripheral T-cell pool. Enhanced thymic function should
also secure a diverse T-cell repertoire as it will concurrently
offset an otherwise homeostatic expansion of an only limited
number of mature T cells. Thus, the clinical use of Fgf7 in
transplantation medicine may efficiently restore the T-cell
compartment and its competence for an effective adaptive
immune response. Based on the understanding that interactions
between developing thymocytes and TECs determine thymic
function, enhanced endogenous production of the cytoprotec-
tive Fgf7 may thus constitute an adjunct strategy for the
treatment of thymic GVHD. However, expression of Fgf7 is
subject to a negative regulation by a standard component of
GVHD therapy, namely glucocorticoids, as this drug decreases
Fgf7 mRNA in a time- and concentration-dependent manner
[229]. The administration of pharmacological doses of Fgf7
prior to conditioning may therefore be needed to compensate
at least for the loss of the physiological production of Fgf7
secondary to GVHD prophylaxis with corticosteroids.
Conclusions
GVHD has traditionally been assessed and graded in the skin,
gut, and liver. Growing clinical and mostly experimental
evidence now argues that the thymusmay actually constitute a
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primary target of allorecognition. The ensuing changes in
thymic T-cell maturation and TCR repertoire selection
account for both an increased susceptibility for infectious
complications and autoimmune pathology typically observed
in a population of long-term survivors after allogeneic HSCT.
The development of minimally invasive tools for the
diagnosis of thymic GVHD (such as advanced imaging or
biomarkers) will therefore be needed to monitor strategies that
should ameliorate functional damage brought about by
GVHD to the processes of T-cell maturation and selection.
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